Q4 2024 Management View CEO Prahlad Singh highlighted that Revvity achieved 6% organic growth in Q4 2024, with adjusted operating margins exceeding 30% and adjusted EPS reaching $1.42, surpassing ...
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on ...
Barclays raised the firm’s price target on Revvity (RVTY) to $28 from $23 and keeps an Overweight rating on the shares. The firm says the life ...
Revvity Inc (RVTY) reports robust Q4 results with 6% organic growth and a 30.3% adjusted operating margin, while navigating ...
Revvity's 2025 Guidance Signals Cautious Optimism Amid Slower-Than-Expected Pharma Spending Recovery
Finally, the applied genomics segment should see continued growth as the cost of sequencing goes down, increasing sequencing by genetic labs and a need for Revvity products. The life sciences ...
Attendees can explore these technologies and more at Revvity’s booth (#1318), where over 40 products from its life sciences portfolio will be showcased. These include solutions for assay ...
Subscribe for FREE Attendees can explore these technologies and more at Revvity’s booth (#1318), where over 40 products from its life sciences portfolio will be showcased. These include solutions for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback